Search
Palvella Therapeutics Inc
PVLAAdd to Watchlist
146.330USD
+0.180+0.12%
Close 11-02 16:00（ET）
2.11BMarket Cap
LossP/E TTM
Palvella Therapeutics Inc (PVLA) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to Palvella Therapeutics Inc in the past month.
Buy
5 Strong Buy
12 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
228.375USD+54.86%
PVLA Analyst Recommendation Trends
In the current month, PVLA has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PVLA average Analyst price target in the last month is 228.375.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
4
4
4
4
5
4
4
12
12
12
12
12
12
12
12
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
16
16
16
16
17
16
16
PVLA Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
11
8
0
0
23
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Financial Forecasting
Based on analysts' estimates, PVLA EPS is projected to reach -1.793 in FY2026Q3, following reported EPS of -1.523 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.91
-0.93
-1.16
-1.79
-2.14
Actual
-1.07
-1.20
-1.52
--
--
Surprise
-17.51%
-29.27%
-31.40%
--
--
FAQs
What is Palvella Therapeutics Inc's price target?
Analysts forecast that Palvella Therapeutics Inc's price target is USD 228.38, with the highest forecast at USD 267.00 and the lowest forecast at USD 205.00.
How have Palvella Therapeutics IncPVLA's recent earnings per share performed?
The market expectation was USD -1.52, while Palvella Therapeutics IncPVLA's earnings per share (EPS) for the previous quarter was USD -1.20. EPS for the next quarter is expected at USD -1.79.
What is the analyst rating for Palvella Therapeutics Inc?
Based on the ratings of Palvella Therapeutics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.